Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 6/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19681567 | 0.91 | FURIN (0.39) | FURINSIRT5NPY1RNPY4R | |
| SCHEMBL27148471 | 0.91 | FURIN (0.34) | SIRT2SIRT1FURINSIRT5ROCK2 | |
| SCHEMBL27152493 | 0.88 | ROCK2 (0.43) | FURINROCK2 | |
| SCHEMBL27152491 | 0.88 | ROCK2 (0.43) | FURINROCK2 | |
| SCHEMBL30874648 | 0.86 | TLR2 (0.41) | SIRT2SIRT1SIRT5 | |
| SCHEMBL15699736 | 0.86 | FURIN (0.40) | SIRT1FURINSIRT5NPY1RNPY4R | |
| SCHEMBL25787504 | 0.86 | FURIN (0.40) | SIRT1FURINSIRT5NPY1RNPY4R | |
| SCHEMBL22138596 | 0.85 | FURIN (0.39) | FURINROCK2NPY1RNPY4R | |
| SCHEMBL20705515 | 0.85 | FURIN (0.39) | FURINROCK2NPY1RNPY4R | |
| SCHEMBL30297062 | 0.85 | HTT (0.41) | SIRT2SIRT1FURINNPY1RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | SIRT2 3240/4885SIRT1 4007/4885FURIN 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.